Raymond James analyst Tiago Fauth resumed coverage of Ionis Pharmaceuticals (IONS) with an Outperform rating and $104 price target The firm sees further upside in the shares given the company’s “fundamentally improved story.” Ionis ‘ stronger than expected severe hypertriglyceridemia readout positions Tryngolza as a “launch to own into 2026 and beyond,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $111 from $100 at BofA
- Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors
- Ionis Pharmaceuticals management to meet with Oppenheimer
- Ionis: Olezarsen’s Expanded Global Opportunity and Strengthened Royalty Streams Support Reiterated Buy and $120 Target
- Arrowhead price target lowered to $81 from $84 at BofA